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CELL CULTURE METHOD AND APPARATUS 
LOR MECHANICALLY STIMULATING 
CELLS
BACKGROUND
The present invention generally relates to a cell culture 
method and apparatus for mechanically stimulating cells, 
including bone cells, ligament cells, tendon cells, cartilage 
cells, muscle cells, blood vessel cells, and nerve cells. Cell 
and tissue graft therapy have been used to treat defects for 
many clinical disorders, including trauma and cancer. 
Autografts and allografts have also been used as grafting 
treatments for tissue repair. However, there is a limited supply 
of tissue that is available for autograft transplantation. 
Autografting requires an additional suigery which can lead to 
donor site morbidity and pain. Allografts have the risks of 
disease transmission and transplant failure due to immune 
response, fracture, or non-union. Due to the limitations of 
grafting, alternative therapies such as tissue engineering can 
be used, including three-dimensional tissue engineering.
SUMMARY
Mechanical loading can enhance cell growth and engineer­
ing tissue development. For example, mechanical loading can 
increase bone cell proliferation and matrix production in 
vitro. Mechanical loading can also increase bone formation in 
vivo, and can help regulate bone tissue mechanical properties. 
Cell adaptation to mechanical loading is believed to be medi­
ated by cell mechanotransduction, which is the process of 
cells detecting mechanical stimuli and converting them into 
biochemical signals. These signals act on effector cells (e.g., 
osteoclasts and osteoblasts in bone) to carry out the tissue 
level adaptations. Cell shear stress induced by fluid flow in the 
porous spaces of bone can act as a mechanical stimulus in 
activating mechanotransduction signaling and mediating 
adaptation. In vivo levels of cell shear stress are estimated to 
be in the range of 0.8-3 Pa. Consequently, fluid flow-induced 
shear stress can be used as a mechanical stimulus to study 
mechanotransduction in vitro. Cell mechanotransduction can 
be analyzed by monitoring media that has flown through a 
flow chamber housing cells. Additionally, cells can behave 
differently when cultured in a three-dimensional environment 
than in a two-dimensional monolayer.
In some embodiments of the present invention, a cell cul­
ture assembly is provided. The cell culture assembly can 
include a flow chamber positioned in a fluid path and a sup­
port comprising cells positioned within the flow chamber to 
expose the cells to the fluid path. The cell culture assembly 
can further include a means for producing a steady flow of 
fluid in the fluid path to transport nutrients to the cells and to 
carry conditioned media away from the cells, and a means for 
producing an oscillatory flow of fluid in the fluid path simul­
taneously with producing the steady flow of fluid in the fluid 
path to mechanically stimulate the cells.
Some embodiments of the present invention provide a cell 
culture assembly. The cell culture assembly can include a 
fluid path through which fluid flows in the cell culture assem­
bly. The cell culture assembly can include a flow chamber 
positioned in the fluid path. The cell culture assembly can 
further include a support positioned within the flow chamber 
and the support may include cells. The cell culture assembly 
can also include a first pump and a second pump positioned in 
fluid communication with the flow chamber. The first pump 
can be adapted to produce a steady flow of fluid in the fluid 
path. The second pump can be adapted to produce an oscil­
1
latory flow of fluid in the fluid path simultaneously with 
production of the steady flow of fluid.
In some embodiments of the present invention, a method 
for culturing cells is provided. The method can include pro­
viding a flow chamber positioned in a fluid path. The method 
can further include providing a support positioned within the 
flow chamber, the support comprising cells. The method can 
also include transporting fluid in the fluid path at a substan­
tially steady flow rate to transport fluid over the cells. The 
method can further include transporting fluid in the fluid path 
at a substantially oscillatory flow rate simultaneously with 
transporting fluid in the fluid path at a substantially steady 
flow rate.
Other features and aspects of the invention will become 
apparent by consideration of the detailed description, accom­
panying drawings and claims.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic diagram of a cell culture assembly 
according to one embodiment of the present invention, the 
cell culture assembly including a plurality of flow chambers.
FIG. 2 is a cross-sectional view of one of the flow chambers 
of FIG. 1.
FIG. 3 is a bar graph illustrating experimental results for 
culturing bone cells in a cell culture assembly according to 
one embodiment of the present invention, as described in 
Examples 1 and 2.
DETAILED DESCRIPTION
Before any embodiments of the invention are explained in 
detail, it is to be understood that the invention is not limited in 
its application to the details of construction and the arrange­
ment of components set forth in the following description or 
illustrated in the following drawings. The invention is capable 
of other embodiments and of being practiced or of being 
carried out in various ways. Also, it is to be understood that 
the phraseology and terminology used herein is for the pur­
pose of description and should not be regarded as limiting. 
The use of “including,” “comprising,” or “having” and varia­
tions thereof herein is meant to encompass the items listed 
thereafter and equivalents thereof as well as additional items. 
Unless specified or limited otherwise, the terms “mounted,” 
“connected,” “supported,” and “coupled” and variations 
thereof are used broadly and encompass both direct and indi­
rect mountings, connections, supports, and couplings. Fur­
ther, “connected” and “coupled” are not restricted to physical 
or mechanical connections or couplings. Furthermore, terms 
such as “front,” “rear,” “top,” “bottom,” and the like are only 
used to describe elements as they relate to one another, but are 
in no way meant to recite specific orientations of the appara­
tus, to indicate or imply necessary or required orientations of 
the apparatus, or to specify how the invention described 
herein will be used, mounted, displayed, or positioned in use.
The present invention relates to cell culture assemblies that 
employ a steady flow of fluid and an oscillatory flow of fluid 
to mechanically stimulate cells. The focus of the description 
below will be on a cell culture assembly for culturing bone 
cells on tissue engineering scaffolds. However, it should be 
noted that the present invention can be extended to the stimu­
lation of other types of cells on various types of supports 
without departing from the spirit and scope of the present 
invention. That is, the present invention can be extended to the 
stimulation of a variety of cells, including, without limitation, 
bone cells, ligament cells, tendon cells, cartilage cells, muscle 
cells (e.g., skeletal muscle cells, cardiac muscle cells and
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smooth muscle cells), blood vessel cells, and nerve cells. 
Various aspects of the present invention have been described 
in a paper by J. L. Vance, S. A. Galley, and S. W. Donahue, 
entitled, “Mechanical stimulation of MC3T3 osteoblastic 
cells in a bone tissue engineering bioreactor enhances PGE2 
release,” which was presented at the 51 st Annual Meeting of 
the Orthopaedic Research Society in Washington DC on Feb. 
21-23, 2005, and which is incorporated herein by reference.
As used herein and in the appended claims, the terms 
“upstream” and “downstream” refer to the direction of steady 
fluid movement in a cell culture assembly. That is, the term 
“upstream” is used to describe any location, element or pro­
cess that occurs prior to the point or area being referred to 
relative to the direction of steady (i.e., not oscillatory) fluid 
movement in a cell culture assembly, whereas the term 
“downstream” is used to describe any location, element or 
process that occurs subsequent to the point or area of refer­
ence with respect to steady fluid movement in the cell culture 
assembly. Although oscillatory flow in the cell culture assem­
bly may at least temporarily reverse the direction of fluid 
movement, the terms “upstream” and “downstream” remain 
defined relative to the steady flow. Furthermore, the terms 
“upstream” and “downstream” are defined assuming a posi­
tive steady flow in the cell culture assembly (i.e., not suction) 
from a first pump and a second pump to one or more flow 
chambers. The steady flow of fluid can include negative, 
reverse steady flow, but such negatively directed flow will not 
affect how “upstream” and “downstream” are defined herein.
As used herein and in the appended claims, the term “fluid 
path” refers collectively to those areas in the cell culture 
assembly through which fluid passes. A “fluid path” can refer 
to an entire path followed by fluid through the cell culture 
assembly or can refer to a portion of that path.
As used herein and in the appended claims, the term “flow 
chamber” refers to a reservoir that is positioned in a fluid path 
to expose at least a portion of the interior of the flow chamber 
to the fluid flowing in the fluid path, the flow chamber being 
in fluid communication with the fluid path. In some embodi­
ments, the flow chamber serves as the final destination of the 
fluid path, and the fluid need not necessarily flow through the 
flow chamber.
As used herein and in the appended claims, the term “sup­
port” refers to any two-dimensional or three-dimensional 
structure to which the cells may be bound, or within which the 
cells can be contained. The “support” can include porous or 
nonporous material. The “support” can be biologically modi­
fied to enhance binding of the cells of interest, including 
having ligands adsorbed to the support to promote the binding 
of cell receptors of interest.
As used herein and in the appended claims, the term “cells” 
refers to a variety of cells including, but not limited to, at least 
one of bone cells (e.g., osteoblasts, osteoclasts, etc.), ligament 
cells (e.g., fibroblasts, etc.), tendon cells (e.g., fibroblasts, 
etc.), cartilage cells (e.g., chondrocytes, etc.), muscle cells 
(e.g., skeletal muscle cells, cardiac muscle cells, smooth 
muscle cells, etc.), blood vessel cells (e.g., smooth muscle 
cells, endothelial cells, etc.), and nerve cells (e.g., neurons, 
astrocytes, oligodendrocytes, etc.).
As used herein and in the appended claims, the term 
“pump” refers to a device that moves a fluid (i.e., a liquid or 
gas) by pressure and/or suction.
As used herein and in the appended claims, the term 
“steady flow” refers to a flow having a substantially steady 
magnitude that is substantially either all positive or all nega­
tive.
As used herein and in the appended claims, the term “oscil­
latory flow” refers to a flow having an oscillatory magnitude.
3
The oscillatory flow includes a symmetrically oscillatory 
magnitude, an asymmetrically oscillating magnitude, and 
combinations thereof. In some embodiments, the oscillatory 
flow includes a positive portion and a negative portion. In 
some embodiments, the oscillatory flow includes pulsatile 
flow, wherein the flow is oscillatory in magnitude, but is either 
all positive or all negative.
As used herein and in the appended claims, the term “bio­
molecule” refers to a molecule, or a derivative thereof, that 
occurs in or is formed by a living cell. A biomolecule can 
include, without limitation, at least one of an amino acid, a 
nucleic acid, a polypeptide, a polynucleotide, a lipid, a phos­
pholipid, a saccharide, a polysaccharide, and combinations 
thereof. Furthermore, a biomolecule can include, without 
limitation, at least one of mRNA, total RNA, genomic DNA, 
plasmid DNA, plant DNA, a protein, a hormone, a growth 
factor, an antibody, an antigen, and combinations thereof.
As used herein and in the appended claims, the term “con­
ditioned media” refers to experimental culture media that has 
flown through the cell culture assembly, and which can be 
used for biochemical analysis. For example, the conditioned 
media can be collected and then analyzed for the presence of 
a biomolecule of interest. In some embodiments, the condi­
tioned media can include cellular waste products.
As used herein and in the appended claims, the term “injec­
tion port” refers to a point in the fluid path wherein a biomol­
ecule may be delivered into the fluid path. An “injection port” 
may be located at any point along the fluid path to allow a 
biomolecule to be delivered at any point along the fluid path.
FIGS. 1 and 2 illustrate a cell culture assembly 100 for 
applying a steady flow of fluid and an oscillatory flow of fluid 
to cells 102 according to one embodiment of the invention. As 
shown in FIG. 1, the cell culture assembly 100 includes a fluid 
path 105 through which fluid flows in the cell culture assem­
bly 100, a first pump 110 forproducing a steady flow of fluid, 
and a second pump 115 for producing an oscillatory flow of 
fluid. The cell culture assembly 100, as shown in FIG. 1, 
further includes a first connector 120 (e.g., a three-way valve) 
positioned in the fluid path 105 to combine the steady flow 
and the oscillatory flow of fluid; a detector 125 for detecting 
at least one of the steady flow and the oscillatory flow of fluid; 
a controller 130 for controlling the flow rate of the steady flow 
of fluid, and the flow rate and frequency of the oscillatory flow 
of fluid; a media source 132 (e.g., a syringe) which allows for 
the transfer of fresh media into the fluid path 105 sub stantially 
without contamination via a second connector 122 (e.g., a 
three-way valve); and an injection port 135 which can be used 
in some embodiments to introduce a biomolecule of interest 
to the fluid path 105. As shown by FIGS. 1 and 2, the cell 
culture assembly 100 also includes one or more flow cham­
bers 145, one or more supports 150 comprising cells 102, and 
one or more collection reservoirs 155. The fluid flowing 
through the fluid path 105 can include, but is not limited to, 
cell culture media. In some embodiments, transfer of fresh 
media into the fluid path 105 via the media source 132 is not 
necessary, and such embodiments do not include the media 
source 132.
The first pump 110 is adapted to produce a steady flow of 
fluid in the fluid path 105 to transport nutrients to the cells 102 
and, in some embodiments, to carry conditioned media 159 
away from the cells 102. The second pump 115 is adapted to 
produce an oscillatory flow of fluid in the fluid path 105 
simultaneously with the production of the steady flow of fluid 
to mechanically stimulate the cells 102. The oscillatory flow 
of fluid generated by the second pump 115 is interposed with 
the steady flow of fluid generated from the first pump 110 via 
the first connector 120. The first connector 120 is positioned
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downstream from the first pump 110 and the second pump 
115 and upstream from the flow chamber 145. The first con­
nector 120 can be positioned at any position in the fluid path 
105 to interpose the steady flow and oscillatory flow of fluid 
produced by the first pump 110 and the second pump 115, 
respectively. In some embodiments, the first pump 110 and 
the second pump 115 are each directly fluidly coupled to each 
flow chamber 145, or to a manifold that supplies fluid to each 
flow chamber 145, and such embodiments do not include the 
first connector 120.
Each flow chamber 145 is positioned downstream from and 
is fluidly coupled to the first connector 120. Each flow cham­
ber 145 includes a support 150. The flow chamber 145 and the 
support 150 are positioned to expose at least a portion of the 
flow chamber 145 and the support 150 to fluid flowing in the 
fluid path 105. Each collection reservoir 155 is positioned 
downstream from and is fluidly coupled to a flow chamber 
145 to collect conditioned media 159 from the flow chamber 
145.
The detector 125 is positioned downstream from one or 
both of the first pump 110 and the second pump 115, and can 
be fluidly coupled to the fluid path 105 at any point along the 
fluid path 105. In some embodiments, the detector 125 
includes a flow probe (e.g., In-line Series Flowprobes flow 
probe, available from Transonic Systems Inc.®, Ithaca, N.Y.) 
for measuring the flow rate and/or frequency of the fluid 
flowing in the fluid path 105. The detector 125 can be used to 
monitor one or more of the following from at least one of the 
first pump 110 and the second pump 115: flow rate, pressure, 
temperature, frequency, etc.
In some embodiments, the detector 125 is adapted to send 
feedback to the controller 130, which can control at least one 
of the first pump 110 and the second pump 115, based upon 
the feedback from the detector 125. The media source 132 can 
be manually activated to deliver fresh media to the fluid path 
105, or the media source 132 can include a programmable 
pump, or a pump that can be controlled by the controller 130, 
similar to that ofthe first pump 110 and the second pump 115. 
Similarly, the injection port 135 can include a manually- 
driven device to introduce a biomolecule of interest to the 
fluid path 105, or the injection port 135 can include an elec­
tronically-driven or programmable pump that can be con­
trolled by the controller 130.
The controller 130 can be connected to the first pump 110, 
the second pump 115, the detector 125, and in some embodi­
ments, the media source 132. In some embodiments, the 
controller 130 of the cell culture assembly 100 is micropro­
cessor-based and is adapted to manipulate and control the first 
pump 110 to control the flow rate of the steady flow of fluid, 
and/or the second pump 115 to control the flow rate and 
frequency of the oscillatory flow of fluid. Additionally, in 
some embodiments, the controller 130 can control the flow 
rate at which fresh media is introduced to the fluid path 105 
via the media source 132. In other embodiments, the control­
ler 130 can include any programmable ornon-programmable 
electronic system, and need not necessarily be microproces­
sor-based. The controller 130 can include any combination of 
hardware and/or software components, and can include more 
than one controller device. In addition, the controller 130 can 
include one or more independently-functioning or depen- 
dently-functioning units, such as a first controller that con­
trols the first pump 110, a second controller that controls the 
second pump 115, and a third controller that controls the 
media source 132. By way of example only, the controller 130 
can include any number of discrete logic elements coupled 
together to perform the same function(s) as described above. 
Still other types of electronic controllers capable of perform­
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ing these function are possible, would be readily recognized 
by those skilled in the art, and fall within the spirit and scope 
of the present invention. In some embodiments, the first pump 
110, the second pump 110, the media source 132, and/or a 
driving device for delivering fluid via the injection port 135 
can be controlled manually, and the controller 130 is not 
required.
The injection port 135 of the illustrated embodiment is 
positioned downstream in the fluid path 105 from the first 
pump 110 and the second pump 115, and upstream from the 
flow chamber 145. Elowever, the injection port 135 can be 
positioned at any point in the fluid path 105 upstream of the 
flow chambers 145 to introduce a biomolecule of interest to 
the fluid path 105 to produce a desired effect in the cells 102. 
For example, in some embodiments, the cells 102 include 
bone cells, and a parathyroid hormone can be delivered (e.g., 
as a bolus injection) at the injection port 135 prior to (e.g., 
about 30 minutes before) activating the second pump 115 and 
introducing the mechanically-stimulating oscillatory flow of 
fluid to the cells 102. Parathyroid hormone has been found to 
increase the responsiveness of bone cells to mechanical 
stimulation. Other biomolecules of interest can be delivered 
in a similar manner, depending on the cells 102 used, and the 
desired effect. In some embodiments, a plurality of injection 
ports 135 can be used to introduce a variety of biomolecules 
to the fluid path 105. In other embodiments, introduction of a 
biomolecule to the fluid path 105 is not necessary, and the cell 
culture assembly 100 does not include an injection port 135.
The first pump 110 can include, but is not limited to, at least 
one of a syringe pump, a peristaltic pump, and some other 
type of linear or non-linear actuator. For example, in some 
embodiments, such as the embodiment illustrated in FIG. 1, 
the first pump 110 includes a programmable syringe pump 
(e.g., a Remote Infuse/Withdraw PF1D 4400 Hpsi Program­
mable Syringe Pump, available from Flarvard Apparatus, 
Flollistion, Mass.) coupled to a first fluid source 152 (e.g., a 
syringe) where the first pump 110 forces the first fluid source 
152 to drive fluid through the fluid path 105. In some embodi­
ments, the first pump 110 includes an electro-magnetically 
driven linear actuator (e.g., LINEAR MOTORS LINMOT® 
P linear motor, available from LinMot® Inc., Delavan, Wis.) 
coupled to the first fluid source 152.
The second pump 115 can include, but is not limited to, at 
least one of a syringe pump and some other type of linear or 
non-linear actuator. For example, in some embodiments, such 
as the embodiment illustrated in FIG. 1, the second pump 115 
includes an electro-magnetically driven linear actuator (e.g., 
LINEAR MOTORS LINMOT® P linear motor, available 
from LinMot® Inc., Delavan, Wis.) coupled to a second fluid 
source 154 (e.g., a syringe), such that the first pump 115 
forces the second fluid source 152 to drive fluid through the 
fluid path 105. It should be understood that the first and 
second fluid sources 152,154 do not need to include syringes, 
but rather can include a variety of types of fluid sources 
known to those of ordinary skill in the art.
In some embodiments, the one or more flow chambers 145 
are defined at least partially by an inner surface 162 of a body 
166. As shown in FIG. 1, the body 166 includes a first portion 
170 and a second portion 174, which can move relative to one 
another to allow a support 150 to be placed inside each flow 
chamber 145. The first portion 170 and the second portion 
174 can be sealed together and held in a sealed positioned by 
one or more closures 176. As shown in FIG. 1, the body 166 
includes two legs 180 coupled to the second portion 174 of the 
body 166. The legs 180 can be used to hold the second portion 
174 in place while a support 150 is positioned within, or 
removed from, each flow chamber 145. The closures 176 and
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legs 180 are illustrated by way of example only, but it should 
be understood by one of ordinary skill in the art that the body 
166 can be sealed and supported in a variety of other ways 
without departing from the spirit and scope of the present 
invention. Furthermore, the body 166 illustrated in FIGS. 1 
and 2 is shown by way of example only. In some embodi­
ments, the body 166 only includes one portion that defines the 
flow chambers 145. Other bodies 166 and flow chamber struc­
tures and shapes can be used without departing from the spirit 
and scope of the present invention.
In the embodiment illustrated in FIG. 1, the flow chambers 
145 are fluidly coupled in parallel to the first pump 110 and 
the second pump 115 via the first connector 120. In some 
embodiments, as shown in FIG. 1, each flow chamber 145 is 
connected to the fluid path 105 downstream of the first con­
nector 120 via a third connector 177 (e.g., a three-way valve). 
In some embodiments employing more than one flow cham­
ber 145, the flow chambers 145 are fluidly coupled in series to 
the first pump 110 and the second pump 115, such that con­
ditioned media 159 flows from one flow chamber 145 into 
another flow chamber 145, and a collection reservoir 155, if 
employed, is fluidly coupled to the last flow chamber 145. In 
the embodiment illustrated in FIG. 1, the body 166 includes 
four flow chambers 145. Fiowever, it should be understood 
that the body 166 can include as few as one flow chamber 145 
and as many as structurally feasible or necessary for a par­
ticular application. For the sake of clarity and brevity, one 
flow chamber 145 will be described herein.
The body 166 can be formed of a variety of materials 
including, but not limited to, a polymer, such as acrylic or 
polycarbonate, and combinations thereof. Accordingly, the 
flow chamber 145 can be formed in the body 166 by a variety 
of methods, including, without limitation, at least one of 
molding, casting, forging and machining. As illustrated in 
FIG. 2, the flow chamber 145 includes an inlet 178 positioned 
to allow fluid to enter the flow chamber 145 and an outlet 182 
positioned to allow fluid to exit the flow chamber 145. Fiow­
ever, in some embodiments, the flow chamber 145 may not 
include an outlet 182 and the flow chamber 145 may serve as 
the final destination in the fluid path 105.
The first portion 170 of the body 166 includes a first bore 
186 defined therein that includes a first opening 188, which is 
in fluid communication with the first connector 120, and a 
second opening 190, which is in fluid communication with 
the inlet 178 ofthe flow chamber 145. The second portion 174 
includes a second bore 192 defined therein that includes a first 
opening 194, which is fluid communication with the outlet 
182 of the flow chamber 145, and a second opening 196, 
which is in fluid communication with the collection reservoir 
155. Thus, the first opening 188 of the first bore 186 defines an 
inlet in the body 166, and the second opening 196 of the 
second bore 192 defines an outlet in the body 166.
The first bore 186 and the second bore 192 can have a 
variety of dimensions. In some embodiments, the first bore 
186 and the second bore 192 are substantially cylindrical and 
each have a diameter. In the embodiment illustrated in FIG. 2, 
the inlet 178 of the flow chamber 145 has a diameter greater 
than that of the first bore 186 and the outlet 182 of the flow 
chamber 145 to allow for the support 150 to be positioned and 
maintained within the flow chamber 145. For example, in 
some embodiments, the diameter of the first bore 186 and the 
diameter of the outlet 182 of the flow chamber 145 are each 
about 0.125 inches, and the diameter of the inlet 178 of the 
flow chamber 145 is about 1 inch to allow the support 150 to 
be positioned within the flow chamber 145.
A recess 195 is further defined in the second portion 174 of 
the body 166 adjacent the inlet 178 of the flow chamber 145.
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As shown in FIG. 2, the recess 195 is also substantially 
cylindrical in shape and has a diameter greater than the diam­
eter of the inlet 178 of the flow chamber 145. A seal-forming 
device 205 (e.g., an o-ring, such as a #11 VITON® o-ring, 
available fromAllorings.com, Inc., Fiampton Falls, N.H.) is 
positioned within the recess 195 to fluidly seal the first portion 
170 and the second portion 174 of the body 166 along an 
interface 210. The seal-forming device 205 includes an aper­
ture with a diameter about equal to that of the first bore 186 to 
allow fluid to pass through the seal-forming device 205 and 
into the flow chamber 145.
In some embodiments, the first opening 188 of the first bore 
186 is fluidly coupled to the first connector 120 via a first 
tubing 225 and the second opening 196 of the second bore 192 
is fluidly coupled to the collection reservoir 155 via a second 
tubing 227. In some embodiments, the first tubing 225 is 
fluidly coupled to the first opening 188 of the first bore 186, 
and the second tubing 227 is fluidly coupled to the outlet 182 
of the flow chamber 145 via barbed male-male connectors, as 
are well-known to those of ordinary skill in the art. Seal­
forming devices 230 (e.g., o-rings) can be used to fluidly seal 
the first tubing 225 and the second tubing 227 to the body 166. 
In some embodiments, the first tubing 225 and the second 
tubing 227 include silicone tubing that is permeable to oxy­
gen and carbon dioxide to ensure gas exchange between the 
cells 102 in the flow chamber 145 and the environment (e.g., 
silicon tubing, available from Flarvard Apparatus, Flolliston, 
Mass.).
In the embodiment illustrated in FIG. 2, the support 150 is 
positioned within the flow chamber 145. In some embodi­
ments, the support 150 can include, but is not limited to, at 
least one of a scaffold, a matrix, a gel, and combinations 
thereof. For example, in some embodiments, the support 150 
includes a substantially cylindrical, porous calcium phos­
phate scaffold (e.g., a 3D Calcium Phosphate Scaffold, avail­
able from BD™ Biosciences, Bedford, Mass,).
Cells 102 can be positioned within the flow chamber 145 in 
a variety of ways. In some embodiments, the cells 102 are 
seeded onto the support 150, and then the seeded support 150 
is positioned within the flow chamber 145. In some embodi­
ments, the cells 102 are suspended within the support 150 
(e.g., within a porous support 150), and then the support 150 
containing the cells 102 is positioned within the flow chamber 
145. In some embodiments, the cells 102 are suspended 
within the flow chamber 145, and the inlet 178 and the outlet 
182 are each fitted with a filter to prevent the cells 102 from 
flowing out of the flow chamber 145. In some embodiments, 
the cells are seeded directly onto the inner surface 162 of the 
body 166, such that the inner surface 162 of the body 166 
functions as a two-dimensional support positioned within the 
flow chamber 145.
The cells 102 can include, but are not limited to, bone cells. 
In some embodiments, the cells 102 include osteoblasts and 
osteoclasts, and combinations thereof. For example, the cells 
102 can include a mouse osteoblastic cell line (e.g., MC3T3 
subclone 4 mouse osteoblastic cell line, available from 
ATCC, The Global Biosource Center™, Manassas, Va.).
In some embodiments, as shown in FIG. 1, the cell culture 
assembly 100 includes four collection reservoirs 155. Fiow­
ever, it should be understood that as few as one collection 
reservoir 155 and as many as structurally feasible, or neces­
sary for a particular application, are possible. The collection 
reservoir 155 can be formed by a variety of methods. In some 
embodiments, as shown in FIG. 1, the collection reservoir 155 
includes a centrifuge tube having a bore defined in its cap 250
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that is sealed by a seal-forming device (e.g., an o-ring), which 
allows for facile removal and replacement of the collection 
reservoir 155.
In operation, regardless of how the cells 102 are positioned 
within the flow chamber 145, fluid is supplied to the first 
pump 110 and the second pump 115, and the first pump 110 
produces a steady flow of fluid and the second pump 115 
produces an oscillatory flow of fluid simultaneously with the 
steady flow of fluid through the fluid path 105. The fluids 
flowing from the first pump 110 and the second pump 115 are 
combined at the first connector 120, and the combined steady 
flow and oscillatory flow of fluid flows the inlet 178 of flow 
chamber 145 (via the first opening 188 of the first bore 186 in 
the first portion 170 of the body 166). The fluid flows through 
the flow chamber 145 and, as the fluid flows through the flow 
chamber 145, the cells 102 seeded on the support 150 are 
subjected to both a steady perfusion of fluid, which transports 
nutrients to the cells 102 and carries conditioned media 159 
away from the cells 102, and an oscillatory flow of fluid 
simultaneously with the steady flow of fluid, which mechani­
cally stimulates the cells 102. The fluid may continue to move 
through the fluid path 105 and exit the flow chamber 145 
through the outlet 182. The fluid can be altered by the cells 
102, becoming conditioned media 159, which can be col­
lected by the collection reservoir 155.
The first pump 110 and the second pump 115 are capable of 
producing a variety of volumetric flow rates, and in addition, 
the second pump 115 is capable of producing a variety of flow 
rates having a variety of frequencies. For example, in some 
embodiments, the second pump 115 produces a volumetric 
flow rate of about 40 mL/min., with a frequency of about 2 Flz. 
In some embodiments, the frequency of the flow produced by 
the second pump 115 is within a generally physiological 
frequency range (e.g., from about 0.1 Flz to about 10 Flz). In 
some embodiments, the first pump 110 is produces a volu­
metric flow rate of about 0.025 mL/min. In some embodi­
ments, the first pump 110 is adapted to produce a constant low 
flow rate perfusion, relative to that produced by the second 
pump 115.
In some embodiments, the second pump 115 is adapted to 
produce a constant oscillatory flow of fluid in the fluid path 
105. In some embodiments, the second pump 115 is adapted 
to produce an intermittent oscillatory flow of fluid. For 
example, in some embodiments, the second pump 115 pro­
duces an oscillatory flow of fluid at least once daily for a 
period of no greater than about 30 minutes.
Cells 102 that may benefit from exposure to a constant 
steady flow of fluid from the first pump 110 combined with a 
constant oscillatory flow of fluid from the second pump 115 
include, but are not limited to, cardiac muscle cells and blood 
vessel cells. Cells 102 that may benefit from exposure to a 
constant steady flow of fluid from the first pump 110 and an 
intermittent oscillatory flow of fluid from the second pump 
115 include, but are not limited to, bone cells, ligament cells, 
tendon cells, and cartilage cells.
The foregoing description of the present invention has been 
presented for purposes of illustration and description. Fur­
thermore, the description is not intended to limit the invention 
to the form disclosed herein. Consequently, variations and 
modifications commensurate with the above teachings, and 
the skill or knowledge of the relevant art, are within the scope 
of the present invention. The embodiments described herein 
are further intended to explain best modes known for practic­
ing the invention and to enable others skilled in the art to 
utilize the invention in such, or other, embodiments and with 
various modifications required by the particular applications 
or uses of the present invention. It is intended that the
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appended claims be construed to include alternative embodi­
ments to the extent permitted by the prior art.
The following working examples are intended to be illus­
trative and not limiting.
EXAMPLE 1
This example describes one embodiment of a cell culture 
assembly 100 of the present invention. Four flow chambers 
145 were machined out of a polycarbonate body 166, and 
each flow chamber 145 housed the cell-seeded supports 150 
during experimentation. The polycarbonate body 166 
included a first portion 170 and a second portion 174, and the 
flow chambers 145 were machined out of the second portion 
174. Four first bores 186 were machined out of the first 
portion 170, and each first bore 186 was positioned in fluid 
communication with the an inlet 178 of each flow chamber 
145. Four second bores 192 were machined out of the second 
portion 174, and each second bore 192 was coupled to an 
outlet 182 of the flow chamber 145. Each flow chamber 145 
had a single 1-inch inlet 178 and a single l/s-inch outlet 182. 
An l/s-inch barbed connector was threaded into an opening 
188 of each first bore 186, and connected to an l/s-inch silicon 
tubing. The body 166 included two steel legs 180 that were 
screwed into a bottom surface of the second portion 174 of the 
polycarbonate body 166. The two steel legs 180 served to 
support the body 166 when the supports 150 were being 
placed into their respective flow chambers 145. Each flow 
chamber 145 was fluidly coupled to a first pump 110, specifi­
cally a syringe pump (available from Flarvard Apparatus, 
Flollistion, Mass.) coupled to a first fluid source 152 for 
producing a steady flow of fluid, and a second pump 115, 
specifically an electromagnetic linear actuator (available 
from Linmot, Delavan, Wis.) coupled to a second fluid source 
154 for producing an oscillatory flow of fluid. Each chamber 
145 was also fluidly coupled to a media source 132, and 
specifically, to a 140 mL syringe. Each flow chamber 145 was 
also fluidly coupled to a collection reservoir 155. The collec­
tion reservoirs 155 used to collect conditioned media 159 
from the cells 102 included 50 mL centrifuge tubes with an 
l/s-inch hole drilled in the cap 250, and an l/s-inch male-male 
tubing barb with an #8 VITON® o-ring (available from Allor- 
ings.com, Inc., Flampton Falls, N.H.) sealing the tubing to the 
cap 250. The first pump 110 provided the constant low flow 
rate perfusion, and the second pump 115 generated a laiger 
magnitude with an oscillatory flow profile. Thus, the cell 
culture assembly 100 provided perfusion with mechanical 
stimulation. Flow rates and profiles were monitored with a 
detector 125. The detector 125 included a flow probe (avail­
able from Transonic Systems Inc., Ithaca, N.Y.). A first con­
nector 120, specifically a three-way valve, was used to com­
bine the fluid flowing from the first pump 110 and the fluid 
flowing from the second pump 115. A second connector 122, 
specifically a three-way valve, allowed for the transfer of 
fresh media from the media source 132 into the system with­
out risk of contamination. Each flow chamber 145 was 
coupled to the first connector 120 via a third connector 117, 
specifically, a three-way valve. The body 166 was kept in an 
incubator at 37° C., 5% carbon dioxide during experimenta­
tion.
EXAMPLE 2
This example describes a method that was used to culture 
cells 102 using the cell culture assembly set forth in Example 
1, compared with cells cultured in static conditions, and cells 
cultured with perfusion flow alone. The supports 150 used
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included a 3D cylindrical, porous calcium phosphate scaffold 
with a 5 mm diameter and a 3.5 mm height. The cells 102 used 
for mechanical stimulation included a mouse osteoblastic cell 
line MC3T3 subclone 4. The cells 102 were first cultured in 
standard MC3T3 media comprising MEM-a (e.g., GIBCO® 
Advanced MEM basal media, available from Invitrogen™, 
Carlsbad, Calif.), 10% fetal bovine serum (e.g., BOVINE 
GROWTE1 SERUM™ fetal bovine serum, available from 
ElyClone, Logan, Utah), and 1% penicillin/streptomycin 
(CELLGRO® penicillin/streptomycin, available from Medi­
ated!, Inc., Elerndon, Va.). The cells 102 were then statically 
seeded on the supports 150 by suspending 100,000 cells 102 
in 40 pi of media and then seeding the resulting suspension 
onto the supports 150. The seeded supports 150 were then 
incubated at 37° C. for 1 hour in a 24-well plate to allow the 
cells 102 to adhere to the supports 150. The cell-seeded sup­
ports 150 were covered with 2 mL of media and allowed to 
incubate for 24 hours prior to being loaded into the flow 
chambers 145. Following the incubation period, the supports 
150 were positioned in the flow chambers 145, which were 
kept in an incubator at 37° C., 5% carbon dioxide. MC3T3 
media perfusion was initiated by the first pump 110 at a rate 
of 0.025 ml/min. Four hours after perfusion began, the first 
mechanical loading bout (i.e., an oscillatory fluid flow) was 
initiated by the second pump 115 at a rate of 40mL/min, with 
a frequency of 1 Flz for 30 min, to allow exposure of the cells 
102 to an intermittent oscillatory flow superimposed with the 
steady perfusion from the first pump 110. One bout of oscil­
latory fluid flow was performed daily for 2 days. For static 
culture conditions, the supports 150 remained in 24-well 
plates with 2 mL of MC3T3 media. For the static cultures, 
media changes were performed every 24 hours. The incubator 
was maintained at 37° C., with 5% C 02 throughout the dura­
tion of the experiment. DNA and prostaglandin E2 were quan­
tified for six supports 150 for each condition (static, perfu­
sion, and perfusion with mechanical stimulation) at both 24 
and 48 hours for a total of 36 supports 150.
The steady flow of fluid was estimated to expose the cells 
102 to a shear stress of about 0.0008 Pa, and the oscillatory 
flow of fluid was estimated to expose the cells 102 to a shear 
stress of 1.3 Pa once daily for a period of 30 min. at 1 Flz for 
the perfusion with mechanical stimulation group. Every 24 
hours, conditioned media 159 was collected and analyzed for 
prostaglandin E2 (PGE2) using a BIOTRAK™ PGE2 com­
petitive enzyme immunoassay (available from Amersham 
Biosciences, Piscataway, N.J.).
The supports 150 were removed after 24 or 48 hours and 
genomic DNA was isolated using the GenomicPrep kit (avail­
able from Amersham Biosciences, Piscataway, N.J.). Cell 
membranes were lysed while the DNA remained hydrated, 
RNA was degraded using RNase A, and protein was precipi­
tated and discarded. DNA was isolated using isopropanol 
precipitation and washed with 70% ethanol. After isolation, 
total DNA was quantified with a Nanodrop Spectrophotom­
eter (available from Nanodrop Technologies, Rockland, 
Del.).
Every 24 hours, conditioned media 159 was collected from 
the flow chambers 145, and the 24-well plates that contained 
the statically cultured supports 150. The conditioned media 
was frozen at -20° C. The PGE2 levels were determined using 
a BIOTRAK™ PGE2 competitive enzyme immunoassay 
(available from Amersham Biosciences, Piscataway, N.J.). 
The assay was performed in duplicate using 50 pL samples 
from all conditioned media 159 samples. The reaction was
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halted prior to endpoint determination using 1M sulfuric acid 
and read at 450 nm using a VERSAmax microplate reader 
(available from Molecular Devices Corporation, Sunnyvale, 
Calif.). The duplicate optical density values were corrected 
for nonspecific binding and averaged, and compared to a 
standard curve to determine the amount of PGE2 in each 
sample. These values were normalized by the total genomic 
DNA in the corresponding support 150. Analysis of variance 
for normalized PGE2 levels were followed up by Fisher’s 
PLSD test at a significance level of 0.05 using SAS statistical 
software.
As shown in FIG. 3, at 24 hours, both perfusion flow alone 
and perfusion flow with mechanical stimulation significantly 
(p<0.001) increased PGE2 release from the cells 102 seeded 
on the supports 150, compared to static controls. The greatest 
increase was in the mechanical stimulation group, which had 
PGE2 levels significantly larger than the other two groups. 
Perfusion flow caused a 2.5-fold increase in PGE2 levels 
compared to static culture after 24 hours, and mechanical 
loading caused a 4.5-fold increase. Similar trends were seen 
at 48 hours; however the difference between the static and 
perfusion groups was not significant. With continued refer­
ence to FIG. 3, at 48 hours, the mechanical group was sig­
nificantly (p<0.034) different from the perfusion and static 
groups. Mechanical stimulation produced about 80% more 
PGE2 release than perfusion flow after 24 hours, and 77% 
more after 48 hours.
What is claimed is:
1. A method for culturing cells, the method comprising:
providing a flow chamber positioned in a fluid path;
providing a porous support positioned within the flow
chamber, the support comprising cells;
transporting fluid in the fluid path at a substantially steady 
flow rate to transport fluid past the cells; and
transporting fluid in the fluid path at a substantially oscil­
latory flow rate simultaneously with transporting fluid in 
the fluid path at a substantially steady flow rate, wherein 
the oscillatory transport of fluid occurs intermittently.
2. The method of claim 1, further comprising detecting at 
least one of the substantially steady flow rate and the substan­
tially oscillatory flow rate in the fluid path.
3. The method of claim 2, further comprising controlling at 
least one of the substantially steady flow rate and the substan­
tially oscillatory flow rate responsive to detecting at least one 
of the substantially steady flow rate and the substantially 
oscillatory flow rate in the fluid path.
4. The method of claim 1, further comprising delivering a 
biomolecule to the fluid path, the biomolecule adapted to 
produce a desired effect in the cells.
5. The method of claim 1, wherein transporting fluid in the 
fluid path at a substantially steady flow rate includes trans­
porting nutrients to the cells and transporting conditioned 
media away from the cells.
6. The method of claim 1, wherein transporting fluid in the 
fluid path at a substantially oscillatory flow rate includes 
mechanically stimulating the cells.
7. The method of claim 1, wherein transporting fluid in the 
fluid path at a substantially steady flow rate includes trans­
porting fluid at a volumetric flow rate ranging from about 0.01 
mL/min to about 3 mL/mm.
8. The method of claim 1, wherein the intermittent oscil­
latory fluid transport occurs thirty minutes per day.
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